Evidence level: B
填一份 CCMQ 体质问卷(60 道题,几分钟)几乎零成本,而一次肠道菌群 16S 测序要 $250,宏基因组要 $350–$650。两套分型都能预测干预效果——但贵的测序带来的预测力提升,到底要达到多少,才对得起那个钱?
正文
判断”测序值不值”用的是一套已经在医院里用了四十年的工具——成本效益分析(CEA),核心指标叫 ICER(增量成本效益比,Incremental Cost-Effectiveness Ratio)。它把”多花的钱”和”多得到的健康”摆到同一条公式里:ICER = ΔC / ΔE。判读规则只有一条——拿 ICER 跟一个叫 WTP 阈值(意愿支付阈值,Willingness-To-Pay)的东西比,低于阈值就算”值”。中国 2024 年的官方 WTP 阈值是 3 倍人均 GDP,约 $40,334/QALY(PMID 12750699);美国学界惯用 $50,000–$150,000/QALY(PMC9753355)。
菌群测序值不值,要用真实的 ICER 表去算。Bajaj 团队在肝硬化场景下跑了一个 Markov 模型(PMID 33071650):1000 名肝硬化患者随访 90 天,把”加做菌群测序”对照”标准临床预测”比,看预测改善能减少多少住院、再住院和肝移植。结果非常坦率——16S 测序($250/样)只要能把住院率压低 2.1% 就回本;低深度宏基因组($350)要压低 2.9%;高深度宏基因组($650)得压低 5.4% 才回本。换句话说,测序越贵、它需要证明自己”更准”的能力就越强。菌群测序在肝硬化场景里能值回票价,但这个”值”是有数学门槛的,不是”测了就赢”。
第二个工具是 DCA(决策曲线分析),由 Vickers 和 Elkin 在 2006 年提出(PMID 17099194)。DCA 把模型的预测力换算成”每个病人净获益几个真阳性”,再画成一条曲线——横轴是”医生愿意干预的最低概率门槛”,纵轴是”净获益”。AUC 高的模型,DCA 不一定高;DCA 高的模型,临床一定更值(PMID 26810254、PMID 8413398)。Van Calster 给出了一个工程化的解读方法叫 test tradeoff(PMID 30241973):模型 A 比模型 B 的净获益高 0.0114,等价于”每 100 个病人多找出 1.14 个真阳性”——也就是”每 88 个人愿意多做一次检查,才能多找出 1 个真病人”。把这个换算搬过来看:菌群测序要在 CCMQ 基础上把净获益推高多少,才值得那个几百到几千块?这是测序成本效益的临床核心问题。
第三个工具是 NRI / IDI / ΔAUC——模型预测力提升的”小指标”系列(PMID 22875755、PMID 20716010)。Pencina 给出了一组经验阈值:ΔAUC > 0.01 算”有意义的提升”;连续 NRI > 0.6 算”强贡献”,0.2–0.6 算”中等”(PMC4688113)。但这些阈值不是金标准——ΔAUC 大小受基线 AUC 影响(基线 0.85 时 ΔAUC 0.01 已经很了不起,基线 0.65 时 ΔAUC 0.05 也只能算凑合),所以单一指标不可独断。临床净获益(NB / INMB)才是终点——同一份数据要在多个 WTP 阈值下反复验,才能定”值不值”。
把这些工具搬进中医体质分型的现实场景:CCMQ 问卷的预测力已经在多个独立数据集上验证过,准确率 0.812–0.936(PMID 35942226),且问卷成本几乎为零;菌群分型在痰湿/湿热/阳虚人群预测应答率时,AUC 多落在 0.74–0.85 区间,单测成本 $250–$650。问题就变成一个对照实验——同一队列同时做 CCMQ 和菌群测序,对照”仅问卷”与”问卷+菌群”,ΔAUC 与 ΔNB 在不同 WTP 阈值下分别是多少?查茵早熟个 6 个月随访就能拿到真实数据。
16S 与宏基因组的成本分层决定这件事的精度。BMC Genomics 2024 在 CRC 队列跑了 156 例样本的双测序对比(PMID 39075388):两者检出的菌群高度不一致——16S 偏向优势菌、宏基因组能到物种/菌株级、宏基因组还能看真菌病毒功能基因。另一篇 PMC10688782 给出了真实的价格分层:16S 短读测序 ~$50/样,浅层宏基因组 ~$80,深层宏基因组 >$150。所以”测序该不该做”的答案分三档:
- 不需测序(ΔAUC ≤ 0.03,NRI(>0) < 0.2):CCMQ 已够,测序无边际价值
- 看场景测(ΔAUC 0.03–0.10,NRI 0.2–0.6):测序在”高成本干预决策点”才有意义,例如是否做肝移植评估、是否上万元级菌群移植方案
- 建议测(ΔAUC ≥ 0.10,NRI > 0.6 且决策点关键):测序换得起这个增量,特别是应答率不高的场景(30–40% 个体不响应通用干预,PMID 12785842)
这套阈值表的边界在哪里?WTP 阈值不是金标准——单一阈值作为政策工具已被批评(PMID 21262069),不同国家、不同病种、不同支付意愿下阈值会差几倍。但”差几倍”也够用——因为测序要不要做的真正决策点,本就是”测序便宜、风险低就用;测序贵、决策重才用”这个粗逻辑。个性化营养系统综述(Value in Health 2021)把所有个性化营养干预的 iNMB 都汇了一遍:均值 iNMB(λ=$50,000)只有 $5,769——绝大多数个性化干预在 WTP 阈值附近挣扎,这是真实世界的”测序值不值”的常态写照。
证据与局限
已验证:
– 菌群测序成本效益在肝硬化场景下经过 Markov 模型标定(PMID 33071650):16S $250 需减少 2.1% 住院才回本,宏基因组 $650 需减少 5.4%
– DCA 决策曲线分析是预测模型临床价值的标准评估方法(PMID 17099194、PMID 26810254、PMID 30241973)
– ΔAUC/NRI/IDI 经验阈值由 Pencina 系列提出(PMID 22875755、PMID 20716010、PMC4688113),但单一指标不独断
– 16S vs 宏基因组在 CRC 队列实证无法相互替代(PMID 39075388);价格分层 50/80/>150 美元(PMC10688782)
– 中国 2024 年 WTP 阈值 = 3 × GDP/capita = $40,334/QALY(PMID 12750699)
部分验证:
– CCMQ 准确率 0.812–0.936(PMID 35942226、PMID 12657019),但跨人群迁移后预测力衰减幅度未量化
– 30–40% 个体不响应通用菌群干预(PMID 12785842),但分层测序能否把这部分人”捞出来”尚未 RCT 验证
待验证:
– 三臂 RCT(CCMQ 仅 / CCMQ+16S / CCMQ+宏基因组)的 ΔAUC、ΔNB、INMB 真实分布
– 在中国 WTP 阈值($40,334/QALY)下,菌群测序的”经济分界点”具体卡在哪一档
– 不同体质亚组(痰湿/湿热/阳虚)的测序边际价值是否异质(亚组级 ICER)
相关阅读
- 填 43 道题,还是花几千块测菌群?——中医体质问卷 vs 菌群测序的”预测力对决”
- 同一队列双套分型,冲突区要不要追加高阶数据?
- 中医体质×菌群干预的应答分层
- 菌群干预剂量-反应曲线的体质特异性
- 研究池子③·生物频率密码
证据等级: B
参考文献: PMID 33071650, PMID 17099194, PMID 30241973, PMID 26810254, PMID 22875755, PMID 20716010, PMID 21262069, PMID 12750699
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Where Is the Economic Divide in Gut Microbiome Sequencing?
Evidence level: B
Completing a CCMQ constitution questionnaire (60 questions, a few minutes) incurs virtually zero cost, whereas a single 16S gut microbiome sequencing test costs approximately $250, and metagenomic sequencing ranges from $350–$650. Both classification systems can predict intervention outcomes—but to what extent must the predictive power of the more expensive sequencing improve to justify the cost?
Main Text
The judgment of whether “sequencing is worth it” relies on a toolset already utilized in hospitals for forty years: Cost-Effectiveness Analysis (CEA). The core metric is the ICER (Incremental Cost-Effectiveness Ratio). It places “extra costs” and “extra health gains” on the same formula: ICER = ΔC / ΔE. The interpretation rule is singular—compare the ICER against a WTP threshold (Willingness-To-Pay). If it falls below the threshold, it is considered “worth it.” China’s official 2024 WTP threshold is 3 times per capita GDP, approximately $40,334/QALY (PMID 12750699); the academic community in the United States typically uses $50,000–$150,000/QALY (PMC9753355).
To determine if microbiome sequencing is worth it, one must calculate using real ICER tables. Bajaj’s team ran a Markov model in a cirrhosis scenario (PMID 33071650): following 1,000 cirrhosis patients for 90 days, they compared “adding microbiome sequencing” against “standard clinical prediction” to see how much hospitalization, readmission, and liver transplantation could be reduced through improved prediction. The results were straightforward—16S sequencing ($250/sample) breaks even if hospitalization rates drop by only 2.1%; low-depth metagenomics ($350) requires a drop of 2.9%; high-depth metagenomics ($650) needs a reduction of 5.4% to break even. In other words, the more expensive the sequencing, the stronger its demonstrated accuracy must be to justify the expense. While microbiome sequencing can recoup its cost in a cirrhosis scenario, this “worth” is subject to mathematical thresholds, not merely “testing may support a win.”
The second tool is DCA (Decision Curve Analysis), proposed by Vickers and Elkin in 2006 (PMID 17099194). DCA converts a model’s predictive power into “net benefit per patient in true positives” and plots it as a curve—the x-axis represents the “minimum probability threshold at which doctors are willing to intervene,” and the y-axis represents “net benefit.” A model with a high AUC does not necessarily have a high DCA; however, a model with a high DCA is clinically more valuable (PMID 26810254, PMID 8413398). Van Calster provided an engineering interpretation method called test tradeoff (PMID 30241973): if Model A yields a net benefit 0.0114 higher than Model B, it is equivalent to “finding 1.14 additional true positives per 100 patients”—meaning “for every 88 people willing to undergo an extra check, one additional true case is identified.” Applying this conversion here: how much must the net benefit be elevated over the CCMQ baseline for microbiome sequencing to justify the hundreds or thousands of dollars? This is the clinical core question regarding sequencing cost-effectiveness.
The third tool is NRI / IDI / ΔAUC—a series of “small metrics” indicating improvements in model predictive power (PMID 22875755, PMID 20716010). Pencina provided a set of empirical thresholds: ΔAUC > 0.01 is considered “meaningful improvement”; continuous NRI > 0.6 counts as “strong contribution,” while 0.2–0.6 is “moderate” (PMC4688113). However, these thresholds are not gold standards—ΔAUC magnitude is influenced by baseline AUC (a ΔAUC of 0.01 is remarkable with a baseline of 0.85, but only adequate with a baseline of 0.65); therefore, no single metric should be decisive. Clinical net benefit (NB / INMB) is the endpoint—the same dataset must be validated repeatedly across multiple WTP thresholds to determine “worth.”
Applying these tools to the reality of Traditional Chinese Medicine (TCM) constitution classification: the predictive power of the CCMQ questionnaire has been validated across multiple independent datasets with accuracy rates of 0.812–0.936 (PMID 35942226), and questionnaire costs are virtually zero; microbiome classification shows AUCs typically falling between 0.74–0.85 when predicting responder rates in phlegm-dampness, damp-heat, and yang-deficiency populations, with single-test costs ranging from $250–$650. The issue becomes a controlled experiment—same cohort performing both CCMQ and microbiome sequencing, comparing “questionnaire only” vs. “questionnaire + microbiome,” calculating ΔAUC and ΔNB across different WTP thresholds. Yin Zao’s 6-month follow-up data can provide real-world answers.
The cost stratification between 16S and metagenomics determines the precision of this matter. BMC Genomics 2024 ran a dual-sequencing comparison on 156 samples in a CRC cohort (PMID 39075388): the microbiota detected by both methods are highly inconsistent—16S tends to favor dominant species, while metagenomics reaches the species/strain level and can also examine fungal/viral functional genes. Another study, PMC10688782, provides real-world price stratification: 16S short-read sequencing ~$50/sample, shallow metagenomics ~$80, deep metagenomics >$150. Thus, the answer to “whether sequencing should be done” falls into three tiers:
- No Sequencing Needed (ΔAUC ≤ 0.03, NRI(>0) < 0.2): CCMQ is sufficient; sequencing offers no marginal value.
- Sequencing Based on Context (ΔAUC 0.03–0.10, NRI 0.2–0.6): Sequencing holds significance only at “high-cost intervention decision points,” such as deciding on liver transplant evaluation or initiating ten-thousand-dollar microbiome transplant protocols.
- Recommended Sequencing (ΔAUC ≥ 0.10, NRI > 0.6 at critical decision points): Sequencing can afford this increment, especially in scenarios with low responder rates (30–40% of individuals do not respond to universal interventions, PMID 12785842).
Where are the boundaries of this threshold table? The WTP threshold is not a gold standard—using a single threshold as a policy tool has been criticized (PMID 21262069), and thresholds vary several-fold across different countries, diseases, and payment willingness. However, a “several-fold difference” is sufficient—because the true decision point for whether to sequence is fundamentally the rough logic: “use sequencing when it is cheap and risk is low; use it only when expensive and the decision is critical.” A systematic review on personalized nutrition systems (Value in Health 2021) aggregated all iNMBs for personalized nutrition interventions: the mean iNMB (λ=$50,000) was only $5,769—the vast majority of personalized interventions struggle near the WTP threshold, which is a realistic depiction of the “worth” of sequencing in the real world.
Evidence and Limitations
Verified:
– Cost-effectiveness of microbiome sequencing in cirrhosis scenarios has been calibrated via Markov modeling (PMID 33071650): 16S at $250 requires a 2.1% reduction in hospitalization to break even; metagenomics at $650 requires a 5.4% reduction.
– DCA (Decision Curve Analysis) is the standard assessment method for clinical value in predictive models (PMID 17099194, PMID 26810254, PMID 30241973).
– Empirical thresholds for ΔAUC/NRI/IDI were proposed by the Pencina series (PMID 22875755, PMID 20716010, PMC4688113), but no single metric should be decisive.
– Empirical evidence in CRC cohorts confirms 16S and metagenomics cannot substitute for one another (PMID 39075388); price stratification is $50/$80/>$150 (PMC10688782).
– China’s 2024 WTP threshold = 3 × GDP/capita = $40,334/QALY (PMID 12750699).
Partially Verified:
– CCMQ accuracy rates of 0.812–0.936 (PMID 35942226, PMID 12657019), but the magnitude of predictive power attenuation after cross-population migration remains unquantified.
– 30–40% of individuals do not respond to universal microbiome interventions (PMID 12785842), but whether stratified sequencing can “rescue” this subgroup remains unverified by RCT.
To Be Verified:
– The true distribution of ΔAUC, ΔNB, and INMB from a three-arm RCT (CCMQ only / CCMQ+16S / CCMQ+Metagenomics).
– The specific tier where the “economic tipping point” for microbiome sequencing falls under China’s WTP threshold ($40,334/QALY).
– Whether the marginal value of sequencing varies heterogeneously across different constitution subgroups (phlegm-dampness/damp-heat/yang-deficiency) at the subgroup level (subgroup-specific ICER).
Related Reading
- Fill 43 Questions or Spend Thousands to Sequence Microbiota? — A “Predictive Power Showdown” Between TCM Constitution Questionnaire and Microbiome Typing
- Same Cohort Dual Classification: Should High-Order Data Be Added in Conflict Zones?
- TCM Constitution × Microbiome Intervention Responder Stratification
- TCM Constitution-Specific Microbiome Intervention Dose-Response Curve
- Research Pool 3 · Bio-Frequency Code
Evidence Level: B
References: PMID 33071650, PMID 17099194, PMID 30241973, PMID 26810254, PMID 22875755, PMID 20716010, PMID 21262069, PMID 12750699
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply